BioAffinity Shares Rise 44% on Lung Cancer Test Study Data [MarketWatch]
bioAffinity Technologies, Inc. (BIAF)
Company Research
Source: MarketWatch
clinical trial studying CyPath Lung, its non-invasive early-stage lung cancer diagnostic test. The San Antonio, Texas, company said the CyPath Lung trial showed 92% sensitivity and 87% specificity in high-risk lung cancer patients who had nodules smaller than 20 millimeters or who didn't have any nodules. Overall, CyPath Lung resulted in testing specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer, BioAffinity said. BioAffinity said CyPath Lung detected multiple forms of lung cancer, including adenocarcinoma, squamous cell carcinoma and small-cell lung cancer. CyPath Lung uses flow cytometry and automated analysis to identify and analyze parameters in lung sputum and whole-cell populations in lung micro-environments which indicate the presence of cancer. BioAffinity shares closed Monday up 5% and are down 10% over the past three months. Write to Chris Wack at chris.wack@wsj.com
Show less
Read more
Impact Snapshot
Event Time:
BIAF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIAF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIAF alerts
High impacting bioAffinity Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
BIAF
News
- Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private PlacementPR Newswire
- bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement [Yahoo! Finance]Yahoo! Finance
- bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private PlacementBusiness Wire
- BioAffinity Technologies Shares Plummet After Stock Sale [MarketWatch]MarketWatch
- WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private PlacementPR Newswire
BIAF
Sec Filings
- 3/20/24 - Form D
- 3/13/24 - Form 8-K
- 3/8/24 - Form 8-K
- BIAF's page on the SEC website